Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares gapped up prior to trading on Wednesday . The stock had previously closed at $208.80, but opened at $225.00. Genmab A/S shares last traded at $225.00, with a volume of 25 shares changing hands.
Genmab A/S Trading Up 0.8%
The company has a market capitalization of $14.99 billion, a price-to-earnings ratio of 12.87 and a beta of 0.91. The firm's 50 day simple moving average is $212.19 and its 200-day simple moving average is $206.10.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $3.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%. The business had revenue of $765.14 million for the quarter, compared to analysts' expectations of $761.09 million.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access